Citations

Mayo Clinic

Showing 10 of 108245 citations.

Microarray Studies of Genomic Oxidative Stress and Cell Cycle Responses in Obstructive Sleep Apnea
Hoffmann, Michał, Singh, Prachi , Wołk, Robert , Romero‐Corral, Abel, Raghavakaimal, Sreekumar, Somers, Virend K. , Singh, Prachi

Antioxidants & Redox Signaling | May 21, 2007 | Volume: 9 | Issue: 6 | Pages: 661-669

10.1089/ars.2007.1589 | PMID 17511582 Get It

Impact of open-access scheduling on realized access
Rohrer, James E. , Bernard, Matthew , Naessens, James M. , Furst, Joseph W. , Kircher, Kyle, Adamson, Steven, Kircher, Kyle J.

Health Services Management Research | May 20, 2007 | Volume: 20 | Issue: 2 | Pages: 134-139

10.1258/095148407780744679 | PMID 17524225 Get It

Open-access or advanced-access scheduling, which opens the clinic calendar to patients without requiring them to schedule far in advance of the visit, is being introduced in primary care for the purpose of improving access. None of the evaluations reported to date have measured differences in actual visits that might be associated with different scheduling systems. The purpose of this study was to compare utilization of visits to primary care providers for patients served by an open-access clinic with utilization patterns of patients served at clinics not using open-access scheduling. We hypothesized that the odds that a continuing patient received more than one primary care visit would be greater in the clinic where open-access scheduling was in use than in comparison clinics. Our study provides mixed support for the hypotheses. After adjustment for case mix, stable chronic patients treated in open-access clinics may sometimes have greater odds of receiving two or more preventive care visits. However, these effects do not occur in all clinics, suggesting that other clinic characteristics may overcome the effects of open-access scheduling.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy
Stephenson, Andrew J. , Scardino, Peter T. , Kattan, Michael W. , Pisansky, Thomas M. , Slawin, Kevin M., Klein, Eric A. , Anscher, Mitchell S. , Michalski, Jeff M. , Lin, Daniel W. , Forman, Jeffrey D., Zeléfsky, Michael J. , Kestin, Larry L. , Roehrborn, Claus G. , Catton, Charles , DeWeese, Theodore L. , Liauw, Stanley L. , Valicenti, Richard K., Kuban, Deborah A., Pollack, Alan , Sandler, Howard M. , Klein, Eric A , Liauw, Stanley L , Kattan, Michael W

Journal of Clinical Oncology | May 19, 2007 | Volume: 25 | Issue: 15 | Pages: 2035-2041

10.1200/jco.2006.08.9607 | PMID 17513807 Get It

Purpose An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence. Patients and Methods Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients. Results The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69. Conclusion Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.
Genetic Deletion of Pregnancy-Associated Plasma Protein-A Is Associated With Resistance to Atherosclerotic Lesion Development in Apolipoprotein E–Deficient Mice Challenged With a High-Fat Diet
Harrington, Sean C., Simari, Robert D., Conover, Cheryl A.

Circulation Research | May 18, 2007 | Volume: 100 | Issue: 12 | Pages: 1696-1702

10.1161/circresaha.106.146183 | PMID 17510462 Get It

Pregnancy-associated plasma protein–A (PAPP-A), a metalloproteinase in the insulin-like growth factor (IGF) system, is markedly upregulated in human atherosclerotic plaque. To determine whether PAPP-A plays an active role in the development of atherosclerosis, we crossed mice lacking apolipoprotein E (ApoE) with PAPP-A–deficient mice, generating ApoE knock-out (KO), PAPP-A KO, wild-type (WT/WT), and ApoE/PAPP-A double KO (KO/KO) mice. These mice were fed a high-fat diet starting at 7 weeks of age. Total serum cholesterol levels were elevated similarly in the ApoE KO and KO/KO mice and were 10-fold higher than in the WT/WT and PAPP-A KO mice. WT/WT and PAPP-A KO mice showed little or no lesion development even after 20 weeks of diet. ApoE KO mice had a progressive increase in aortic lesion area over 20 weeks of diet. In comparison, lesion area was reduced 60% to 80% in KO/KO mice. Lesions of ApoE KO aortas had 8- to 20-fold increases in PAPP-A, IGFBP-4, and IGF-I mRNA levels compared with nonlesional areas, whereas IGF-I receptor levels were equivalent—conditions for enhanced lesional IGF activity. Consistent with this, an in vivo marker of IGF-I receptor-mediated action was increased 10-fold in lesions from ApoE KO compared with KO/KO aortas. These data indicate that PAPP-A plays a critical role in lesion development in a mouse model of atherosclerosis, at least in part, through amplification of local IGF-I bioavailability.
EGFR-T790M Is a Rare Lung Cancer Susceptibility Allele with Enhanced Kinase Activity
Vikis, Haris G., Sato, Mitsuo , James, Michael A. , Wang, Daolong, Wang, Yian , Wang, Min , Jia, Dongmei , Liu, Yan , Bailey‐Wilson, Joan E. , Pinney, Susan M. , Petersen, Gloria M. , Wiest, Jonathan S., Fain, Pamela R., Schwartz, Ann G. , Gazdar, Adi F. , Gaba, Colette , Rothschild, Henry, Mandal, Diptasri , Kupert, Elena, Seminara, Daniela, Viswanathan, Avinash, Govindan, Ramaswamy , Anderson, Marshall W., You, Ming , Amos, Christopher I. , Andrade, Mariza de , Yang, Ping , Minna, John Dorrance , Wilson, Richard K , Pinney, Susan M , Govindan, Ramaswamy

Cancer Research | May 18, 2007 | Volume: 67 | Issue: 10 | Pages: 4665-4670

10.1158/0008-5472.can-07-0217 | PMID 17510392 Get It

Abstract The use of tyrosine kinase inhibitors (TKI) has yielded great success in treatment of lung adenocarcinomas. However, patients who develop resistance to TKI treatment often acquire a somatic resistance mutation (T790M) located in the catalytic cleft of the epidermal growth factor receptor (EGFR) enzyme. Recently, a report describing EGFR-T790M as a germ-line mutation suggested that this mutation may be associated with inherited susceptibility to lung cancer. Contrary to previous reports, our analysis indicates that the T790M mutation confers increased Y992 and Y1068 phosphorylation levels. In a human bronchial epithelial cell line, overexpression of EGFR-T790M displayed a growth advantage over wild-type (WT) EGFR. We also screened 237 lung cancer family probands, in addition to 45 bronchoalveolar tumors, and found that none of them contained the EGFR-T790M mutation. Our observations show that EGFR-T790M provides a proliferative advantage with respect to WT EGFR and suggest that the enhanced kinase activity of this mutant is the basis for rare cases of inherited susceptibility to lung cancer. [Cancer Res 2007;67(10):4665–70]
Immune Mechanisms in Non–Hodgkin Lymphoma: Joint Effects of the TNF G308A and IL10 T3575A Polymorphisms with Non–Hodgkin Lymphoma Risk Factors
Wang, Sophia , Cerhan, James R. , Colt, Joanne S., Morton, Lindsay M. , Severson, Richard K., Rothman, Nathaniel , Hartge, Patricia, Cozen, Wendy , Engels, Eric A. , Davis, Scott , Chanock, Stephen Jacob , Cerhan, James R , Morton, Lindsay M , Wang, Sophia S

Cancer Research | May 18, 2007 | Volume: 67 | Issue: 10 | Pages: 5042-5054

10.1158/0008-5472.can-06-4752 | PMID 17510437 Get It

Abstract Two common single nucleotide polymorphisms in immunoregulatory genes (TNF G308A, rs1800629 and IL10 T3575A, rs1800890) have been recently reported as risk factors for non–Hodgkin lymphoma (NHL) in a large pooled analysis. We systematically investigated the effects of other established NHL risk factors in relation to the tumor necrosis factor (TNF) G308A or interleukin 10 (IL10) T3575A genotypes. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) from 1,172 cases and 982 population-based controls in a U.S. multicenter study. We investigated NHL overall and two common subtypes [diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma]. NHL risks were increased among those with both an autoimmune condition and the TNF G308A GA/AA (ORNHL, 2.1; 95% CI, 1.0–4.2) or the IL10 T3575A TA/AA genotype (ORNHL, 1.6; 95% CI, 0.9–2.6) compared with individuals without an autoimmune condition and with the common TNF G308A GG or IL10 T3575A TT genotype, respectively; results were similar for DLBCL and follicular lymphoma. We found that elevated DLBCL risk associated with last-born status was more pronounced among those with TNF G308A GA/AA (ORDLBCL, 2.7; 95% CI, 1.1–6.4) or IL10 T3575A TA/AA (ORDLBCL, 2.9; 95% CI, 1.6–5.2). Similarly, elevated DLBCL risk associated with obesity (body mass index, ≥35 versus &lt;25 kg/m2) was observed only among those with TNF G308A GA/AA (ORDLBCL, 2.5; 95% CI, 1.1–5.7) or IL10 T3575A TA/AA genotypes (ORDLBCL, 2.0; 95% CI, 1.1–3.5). These exploratory results require replication but provide evidence that autoimmune conditions, late birth order, and obesity act partly through a common inflammatory pathway, posing a greater risk to individuals with variant TNF and IL10 genotypes than those with wild-type alleles. [Cancer Res 2007;67(10):5042–54]
Cystolithiasis With Concentric Mural Calcification Following Transurethral Microwave Thermotherapy
Trost, Landon , Siddiqui, Sameer , Gettman, Matthew T.

Journal of Urology | May 17, 2007 | Volume: 177 | Issue: 6 | Pages: 2339-2339

10.1016/j.juro.2007.02.030 | PMID 17509354 Get It

What Tidal Volumes Should Be Used in Patients without Acute Lung Injury?
Schultz, Marcus J. , Haitsma, Jack J. , Slutsky, Arthur S. , Warltier, David C., Gajic, Ognjen , Schultz, Marcus J

Anesthesiology | May 17, 2007 | Volume: 106 | Issue: 6 | Pages: 1226-1231

10.1097/01.anes.0000267607.25011.e8 | PMID 17525599 Get It

Mechanical ventilation practice has changed over the past few decades, with tidal volumes (VT) decreasing significantly, especially in patients with acute lung injury (ALI). Patients without acute lung injury are still ventilated with large--and perhaps too large--VT. Studies of ventilator-associated lung injury in subjects without ALI demonstrate inconsistent results. Retrospective clinical studies, however, suggest that the use of large VT favors the development of lung injury in these patients. Side effects associated with the use of lower VT in patients with ALI seem to be minimal. Assuming that this will be the case in patients without ALI/acute respiratory distress syndrome too, the authors suggest that the use of lower VT should be considered in all mechanically ventilated patients whether they have ALI or not. Prospective studies should be performed to evaluate optimal ventilator management strategies for patients without ALI.
Incidence of Propofol Infusion Syndrome during Noninvasive Radiofrequency Ablation for Atrial Flutter or Fibrillation
Cravens, Grant T., Packer, Douglas L. , Johnson, Michael E.

Anesthesiology | May 17, 2007 | Volume: 106 | Issue: 6 | Pages: 1134-1138

10.1097/01.anes.0000265421.40477.a3 | PMID 17525588 Get It

Background Propofol infusion syndrome is first manifest by unexplained metabolic acidosis. Its incidence is unknown. Methods Charts of all patients undergoing nonsurgical, catheter radiofrequency ablation for atrial flutter or fibrillation from 1999 through 2001 at Mayo Clinic Rochester, who received propofol and had an arterial blood gas drawn during the procedure, were reviewed retrospectively for metabolic acidosis, prospectively defined as base excess -2 or less. Of 301 radiofrequency ablation cases, 55 had an arterial blood gas. Virtually all radiofrequency ablation patients received propofol, so they could not be used as nonpropofol controls. Instead, all carotid endarterectomy patients in 2000 who did not receive propofol and had an arterial blood gas drawn after anesthetic induction and before surgical incision were used as a comparator group. Results In propofol radiofrequency ablation patients with no apparent cause of metabolic acidosis besides propofol, 13 of 55 (24%) had base excess of -2 or less, versus 22 of 267 carotid patients (8.2%) (P<0.01). Maximal negative base excess was -4.2+/-1.7 in these propofol patients and was not correlated with propofol dose, age, or fluid dose, versus base excess of -3.2+/-1.5 in carotid patients (P>0.05). Propofol patients received prolonged anesthetics (7 h) and high-dose propofol (20 mg/kg). Conclusions This is the first incidence estimate of metabolic acidosis during prolonged propofol infusion and suggests that it is not rare. The study is limited by its retrospective nature and by the lack of baseline arterial blood gas data and will require confirmation by prospective study.
A Combined, Minimally Invasive Transnasal Approach to the Sella Turcica
Nasseri, Shawn S., McCaffrey, Thomas V., Kasperbauer, Jan L. , Atkinson, John L. D.

American Journal of Rhinology | May 16, 2007 | Volume: 12 | Issue: 6 | Pages: 409-416

10.2500/105065898780707883 | PMID 9883297 Get It

The increasing use of endonasal techniques and a new 3-dimensional CT-guided imaging system have allowed us to develop a combined, minimally invasive endonasal approach to the pituitary gland. Thus far, more than 30 patients have undergone an endonasal transsphenoidal approach to the sella using a combined endoscopic approach, with additional selective use of the Instatrak CT-guided imaging system for realtime imaging. Our current technique involves obtaining a preoperative CT using a plastic head frame with registration markers. By using this head frame intraoperatively, real-time localization with CT images in axial, coronal, and sagittal planes can be performed. Using endoscopic techniques and a Papavero-Caspar speculum, the sella is exposed. A combined approach using endoscopes, the operating microscope, and real-time localization is undertaken to expose and resect tumors. We have encountered minimal associated complications in our series, and this method has been progressively modified to improve exposure and safety. Because we are able to visualize the sella without a sublabial incision or septal resection, we have nearly eliminated the need for nasal packing, reduced the average hospital stay to 2.5 days, and improved patient satisfaction.